Becton, Dickinson and Company(BDX) Stock Research - Grey Stern Research

Becton, Dickinson and Company (BDX) Stock Analysis

$237.30 (1.94%)

BDX Financial Performance


Use the table below to view Becton, Dickinson and Company's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $232.78 -
52 Week Low $218.75 -
52 Week High $286.46 -
Market Cap $67.3 Billion 1/11
Gross Margin 46% 9/11
Profit Margin 11% 4/11
EBITDA margin 28% 3/11
Q2 - 2024 Revenue $5.0 Billion 1/11
Q2 - 2024 Earnings $537.0 Million 1/11
Q2 - 2024 Free Cash Flow $381.0 Million 1/11
Trailing 4 Quarters Revenue $19.7 Billion 1/11
Trailing 4 Quarters Earnings $1.4 Billion 1/11
Quarterly Earnings Growth 17% 4/11
Annual Earnings Growth -31% 7/11
Quarterly Revenue Growth 5% 4/11
Annual Revenue Growth 6% 2/11
Cash On Hand $2.4 Billion 1/11
Short Term Debt $2.0 Billion 1/11
Long Term Debt $16.0 Billion 1/11

Becton, Dickinson and Company Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Becton, Dickinson and Company's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 48.79 3/11
PS 3.41 8/11
PB 2.62 6/11
PC 28.10 5/11
Liabilities to Equity 1.11 3/11
ROA 0.03 6/11
ROE 0.05 6/11
Current Ratio 1.90 9/11
Quick Ratio 0.11 6/11
Long Term Debt to Equity 0.62 3/11
Debt to Equity 0.70 3/11
Burn Rate 3.95 5/11
Cash to Cap 0.04 6/11
CCR 0.71 5/11
EV to EBITDA 58.96 8/11
EV to Revenue 4.20 6/11

Company Details

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

CEO: Mr. Thomas Polen

Website: https://www.bd.com

Address: 1 Becton Dr Franklin Lakes, NEW JERSEY

Exchange: New York Stock Exchange

Industry: Medical Instruments & Supplies

Becton, Dickinson and Company Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Becton, Dickinson and Company. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
DENTSPLY SIRONA Inc. XRAY $5.5 Billion
Hologic, Inc. HOLX $18.4 Billion
ResMed Inc. RMD $28.9 Billion
The Cooper Companies, Inc. COO $18.6 Billion
Haemonetics Corporation HAE $4.6 Billion
Teleflex Incorporated TFX $10.4 Billion
West Pharmaceutical Services, Inc. WST $20.7 Billion
AngioDynamics, Inc. ANGO $306.4 Million
ICU Medical, Inc. ICUI $3.1 Billion
Repligen Corporation RGEN $7.9 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
BDX Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 5.0 Billion $537.0 Million
Q1 2024 $ 4.7 Billion $281.0 Million
Q4 2023 $ 5.1 Billion $154.0 Million
Q3 2023 $ 4.9 Billion $407.0 Million
Q2 2023 $ 4.8 Billion $460.0 Million
Q1 2023 $ 4.6 Billion $509.0 Million
Q4 2022 $ 4.8 Billion $287.0 Million
Q3 2022 $ 4.6 Billion $390.0 Million

View All

BDX Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $2.4 Billion $54.2 Billion $18.0 Billion $25.6 Billion
Q1 2024 $1.2 Billion $52.3 Billion $16.1 Billion $25.3 Billion
Q4 2023 $1.4 Billion $52.8 Billion $15.8 Billion $52.8 Billion
Q3 2023 $923.0 Million $53.0 Billion $16.8 Billion $25.9 Billion
Q2 2023 $2.0 Billion $54.4 Billion $18.2 Billion $25.7 Billion
Q1 2023 $612.0 Million $53.1 Billion $16.5 Billion $25.5 Billion
Q4 2022 $1.0 Billion $52.9 Billion $14.8 Billion $25.3 Billion
Q3 2022 $2.6 Billion $53.2 Billion $17.4 Billion $25.5 Billion

View All

BDX Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 $381.0 Million -$134.0 Million $1.2 Billion
Q1 2024 $725.0 Million -$116.0 Million -$247.0 Million
Q4 2023 $1.0 Billion -$294.0 Million $457.0 Million
Q3 2023 $889.0 Million -$191.0 Million -$1.0 Billion
Q2 2023 $3.0 Million -$181.0 Million $1.3 Billion
Q1 2023 $192.0 Million -$208.0 Million -$415.0 Million
Q4 2022 $656.0 Million -$315.0 Million -$1.6 Billion
Q3 2022 $137.0 Million -$243.0 Million $368.0 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions